Roche

Roche

ORG Health Care / Pharmaceuticals Momentum 6.5ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Attention Cascade

$273B market cap (Basel) develops pharmaceuticals, diagnostics, and personalized healthcare solutions. Recent pipeline momentum includes mid-stage diabetes trials for incretin therapy and combination GLP-1/GCG agonist programs; facing U.S. pricing pressure amid regulatory tensions.

Ongoing clinical development pipeline expansion; Phase 2 trials for petrelintide and enicepatide combination therapy for diabetes; incretin shot Phase 2 success in type 1 diabetes.

0.01

PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.

6.5

MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.

ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.

ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.

Roche is getting more coverage than its own momentum predicts — an external catalyst is likely driving attention (primary driver: Attention Cascade).

PSI Intelligence

30-Day Trend

Signal Decomposition

Attention Cascade

3.333

Narrative Drift

0.000

Spectral Shift

0.000

Sentiment-Momentum Divergence

0.000

Source Concentration

0.625

Signal

Roche is getting more coverage than its own momentum predicts — an external catalyst is likely driving attention (primary driver: Attention Cascade).

Driver

Ranked #36 of 87 in Health Care — in line with sector peers. PSI down 0.10 from yesterday (0.11 -> 0.01).

Action

Baseline conditions. Continue standard monitoring cadence. Check for unreported catalysts driving unexpected coverage volume.

Peer Comparison

36 of 87

Sector Rank

+0.25

Peer Z-Score

59%

Sector Percentile

Network Analysis

9 Degree Centrality

Ego Network (top connections)

Centrality History

Entity	Weight	Status
AstraZeneca	4	NEW
Pfizer	4	NEW
PlocamiumAI	3	NEW
Merck	3	NEW
Europe	2	NEW
Novartis	2	NEW
Paris	2	NEW
FDA	1	NEW
U.S. Department of Health and Human Services	1	NEW

Article Coverage (6)

Date	Lane	Title
2026-05-27	Healthcare Marketing	Roche Bets Billions on PathAI to Leapfrog Rivals in the Race For AI-Powered Pathology
2026-05-09	Healthcare M&A	Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09	Healthcare M&A	Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09	Healthcare M&A	Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09	Healthcare M&A	Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs
2026-05-09	Healthcare M&A	Roche Acquires PathAI to Control the Diagnostic Layer That Determines Which Patients Get Which Drugs

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Roche+ Note this entity

Request Access